作者: Emily N. Prendergast , Julia A. Elvin
DOI: 10.1097/GCO.0000000000000335
关键词:
摘要: PURPOSE OF REVIEW This article summarizes advances in the application of next-generation sequencing (NGS) to personalized treatment gynecologic malignancies. RECENT FINDINGS Many recurrent genomic alterations (GA) malignancies have been identified by studies applying NGS tumor tissue, which can provide insights into biology, diagnostic or prognostic information, and potential targeted therapy options. be used assay single genes, portions multiple genes ("hot-spot" panels), complete coding sequence a broad range cancer-associated [i.e. comprehensive profiling (CGP)]. CGP patient's reveals practitioners clinically relevant GA (CRGA) associated biomarker-matched treatments, with goal improving therapeutic response while limiting cumulative chemotherapeutic toxicities. Although use precision medicine for cancers holds much promise, data detailing impact on survival quality life is still accumulating, lagging behind other areas oncology. Enrolling oncology patients genotype-matched trials remains challenging highlights need more molecular-based basket reproductive tract SUMMARY Identification molecular subsets distinct clinical attributes, significance, directed options now feasible practice.